Hepatitis D virus infection

This phase 2 trial tests whether peginterferon lambda, an experimental interferon drug, can safely reduce hepatitis D virus levels in people with chronic infection. Participants receive one of two doses of the drug for 48 weeks, and researchers measure changes in viral load and l…

This phase 2 trial is testing whether adding an experimental drug called JNJ-73763989 to standard oral antivirals can better suppress hepatitis D virus in people who are also infected with hepatitis B. About 52 adults with stable chronic co-infection will receive either the combi…

This early-stage study tested a new treatment approach for adults with chronic hepatitis B or D. Twenty participants received two medications in sequence: P1101 (a type of interferon) followed by an anti-PD1 drug. The main goal was to check safety and tolerability, while also loo…

This completed Phase 3 trial tested a once-daily combination of two drugs, lonafarnib and ritonavir, in 10 adults with chronic hepatitis D. The goal was to see if the regimen is safe and can lower the amount of virus in the blood over 48 weeks of treatment and 24 weeks of follow-…

This study tested an experimental drug called HH-003 in 101 adults with chronic hepatitis delta, a serious liver disease. HH-003 is an antibody that targets hepatitis B virus, which is needed for hepatitis delta to survive. Participants received either a low or high dose of HH-00…

This early-stage study looked at how the drug bulevirtide behaves in people with chronic hepatitis D who also have normal or impaired kidney function. Researchers measured drug levels in the blood, its effect on bile acids, and overall safety. The study enrolled 41 adults and gav…

This study tested whether treating private well water with ultraviolet (UV) light can prevent stomach and respiratory infections in children under 5. Researchers gave 28 Pennsylvania households either a real UV device or a fake one and tracked illness symptoms via weekly texts. T…

Researchers are surveying people in Thailand who have chronic hepatitis B to find out how many also carry hepatitis D, a virus that can make liver disease worse. The study focuses on groups at higher risk, including people who inject drugs, men who have sex with men, prisoners, a…

This study follows adults in Zambia who have both HIV and chronic hepatitis B to track liver health over up to 10 years. Researchers aim to understand how current HIV treatments affect hepatitis B and liver damage, and to identify factors that lead to serious outcomes like liver …

This study followed 326 adults in Zambia with chronic hepatitis B for up to 5 years. Researchers tracked how the virus behaves, how many patients need treatment, and how many develop serious liver problems like cirrhosis or liver cancer. The goal was to better understand the dise…

This study looked at how people with chronic liver disease (like hepatitis B, C, or fatty liver) respond to COVID-19 vaccines. About 233 adults had three visits over a year to check their immune response and see if they got COVID-19. The goal was to understand if liver disease af…

This completed Phase 1 study looked at how the drug bulevirtide (Hepcludex) behaves in the body of people with normal liver function and those with liver impairment. Researchers measured drug levels in the blood and how quickly it is cleared. The study involved 74 participants an…

This early-stage study tested the safety and how the body processes a new drug called ABI-6250 in 40 healthy adults. Participants received either the drug or a placebo, and researchers measured side effects and drug levels in the blood. The goal was to gather safety information b…